Our broad portfolio consists of multiplex panels that allow you to choose, within the panel, analytes that best meet your needs. On a separate tab you can choose the premixed cytokine format or a single plex kit.
Cell Signaling Kits & MAPmates™
Choose fixed kits that allow you to explore entire pathways or processes. Or design your own kits by choosing single plex MAPmates™, following the provided guidelines.
The following MAPmates™ should not be plexed together:
-MAPmates™ that require a different assay buffer
-Phospho-specific and total MAPmate™ pairs, e.g. total GSK3β and GSK3β (Ser 9)
-PanTyr and site-specific MAPmates™, e.g. Phospho-EGF Receptor and phospho-STAT1 (Tyr701)
-More than 1 phospho-MAPmate™ for a single target (Akt, STAT3)
-GAPDH and β-Tubulin cannot be plexed with kits or MAPmates™ containing panTyr
.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Select A Species, Panel Type, Kit or Sample Type
To begin designing your MILLIPLEX® MAP kit select a species, a panel type or kit of interest.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Species
Panel Type
Selected Kit
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
96-Well Plate
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
Add Additional Reagents (Buffer and Detection Kit is required for use with MAPmates)
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
This item has been added to favorites.
The Product Has Been Added To Your Cart
You can now customize another kit, choose a premixed kit, check out or close the ordering tool.
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More
341205
Sigma-AldrichEtoposide - CAS 33419-42-0 - Calbiochem
Etoposide, CAS 33419-42-0, is cell-permeable inhibitor of topoisomerase II inhibitor (IC50 = 59.2 µM). Displays anti-tumor activity.
More>>Etoposide, CAS 33419-42-0, is cell-permeable inhibitor of topoisomerase II inhibitor (IC50 = 59.2 µM). Displays anti-tumor activity. Less<<
Etoposide - CAS 33419-42-0 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
A cell-permeable derivative of podophyllotoxin that acts as a topoisomerase II inhibitor (IC50 = 59.2 µM) has major activity against a number of tumors, including germ cell neoplasms, small cell lung cancer, and malignant lymphoma. Induces apoptosis in mouse thymocytes and in HL-60 human leukemia cells.
Catalogue Number
341205
Brand Family
Calbiochem®
Synonyms
VP-16
References
References
De Lange, A.M., et al. 1995. J. Virol. 69, 2082. Kaufman, S.H., et al. 1993. Cancer Res.53, 3976. Onishi, Y., et al. 1993. Biochim. Biophys. Acta1175, 147. Terada, T., et al. 1993. J. Med. Chem. 36, 1689. Wazniak, A.J., et al. 1991. J. Clin. Oncol.9, 70. Einhorn, L.H., et al. 1988. J. Clin. Oncol.6, 451. Issel, B.F. 1982. Cancer Chemother. Pharmacol.7, 73.
Etoposide, CAS 33419-42-0, is cell-permeable inhibitor of topoisomerase II inhibitor (IC50 = 59.2 µM). Displays anti-tumor activity.
Biological Information
Primary Target
topoisomerase 2
Primary Target IC<sub>50</sub>
59.2 µM inhibiting topoisomerase II
Purity
>95% by HPLC
Physicochemical Information
Cell permeable
Y
Safety Information according to GHS
RTECS
KC0190000
Safety Information
R Phrase
R: 22-45
Harmful if swallowed. May cause cancer.
S Phrase
S: 26-36/37/39-45-53
In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Avoid exposure - obtain special instructions before use.
Storage and Shipping Information
Ship Code
Ambient Temperature Only
Toxicity
Harmful & Carcinogenic / Teratogenic
Storage
+15°C to +30°C
Protect from Light
Protect from light
Do not freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Etoposide - CAS 33419-42-0 - Calbiochem Certificates of Analysis
Title
Lot Number
341205
References
Reference overview
De Lange, A.M., et al. 1995. J. Virol. 69, 2082. Kaufman, S.H., et al. 1993. Cancer Res.53, 3976. Onishi, Y., et al. 1993. Biochim. Biophys. Acta1175, 147. Terada, T., et al. 1993. J. Med. Chem. 36, 1689. Wazniak, A.J., et al. 1991. J. Clin. Oncol.9, 70. Einhorn, L.H., et al. 1988. J. Clin. Oncol.6, 451. Issel, B.F. 1982. Cancer Chemother. Pharmacol.7, 73.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
30-October-2023 JSW
Synonyms
VP-16
Description
A cell-permeable, topoisomerase II inhibitor (IC50 = 59.2 µM). A derivative of podophyllotoxin (Cat. No. 540040) that has major activity against a number of tumors, including germ cell neoplasms, small cell lung cancer, and malignant lymphoma. Induces apoptosis in mouse thymocytes and in HL-60 human leukemia cells.
Form
White solid
CAS number
33419-42-0
RTECS
KC0190000
Chemical formula
C₂₉H₃₂O₁₃
Structure formula
Purity
>95% by HPLC
Solubility
DMSO (25 mg/ml)
Storage
Protect from light +15°C to +30°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity
Harmful & Carcinogenic / Teratogenic
Merck USA index
14, 3886
References
De Lange, A.M., et al. 1995. J. Virol. 69, 2082. Kaufman, S.H., et al. 1993. Cancer Res.53, 3976. Onishi, Y., et al. 1993. Biochim. Biophys. Acta1175, 147. Terada, T., et al. 1993. J. Med. Chem. 36, 1689. Wazniak, A.J., et al. 1991. J. Clin. Oncol.9, 70. Einhorn, L.H., et al. 1988. J. Clin. Oncol.6, 451. Issel, B.F. 1982. Cancer Chemother. Pharmacol.7, 73.